Nonalcoholic Steatohepatitis (NASH) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm and Pipeline Analysis

 Breaking News
  • No posts were found

Nonalcoholic Steatohepatitis (NASH) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm and Pipeline Analysis

May 11
20:40 2021
Nonalcoholic Steatohepatitis (NASH) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm and Pipeline Analysis

Delveinsight Business Research LLP

“Nonalcoholic Steatohepatitis (NASH) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Nonalcoholic Steatohepatitis (NASH) Market.

The Nonalcoholic Steatohepatitis (NASH) Pipeline report embraces in-depth commercial and clinical assessment of the Nonalcoholic Steatohepatitis (NASH) pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic Steatohepatitis (NASH) collaborations, mergers, acquisition, funding, designations, and other product-related details.

The market size of the currently available off-label therapies for the treatment of NASH is expected to experience steady growth until the launch of targeted emerging therapies, while it will decrease thereafter, owing to the good safety and efficacy observed for the drug in the treatment of NASH.

Furthermore, the increase in the number of obese and diabetic patients will drive the market growth for NASH. Overall, the increasing prevalence, awareness of the disease, and promising emerging pipeline therapies will propel the market size forward during the forecast period of 2021–2030.

Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis

Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Nonalcoholic Steatohepatitis (NASH) with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Nonalcoholic Steatohepatitis (NASH) Treatment.

  • Nonalcoholic Steatohepatitis (NASH) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Nonalcoholic Steatohepatitis (NASH) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nonalcoholic Steatohepatitis (NASH) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Scope of the report

  • The Nonalcoholic Steatohepatitis (NASH) Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Nonalcoholic Steatohepatitis (NASH) across the complete product development cycle, including all clinical and non-clinical stages.

  • It comprises detailed profiles of Nonalcoholic Steatohepatitis (NASH) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

  • Detailed research and development progress and clinical trial of Nonalcoholic Steatohepatitis (NASH), results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Nonalcoholic Steatohepatitis (NASH).

The treatment of NASH depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are, however, the first line of treatment. Lifestyle modifications include going for weight loss combined with an active exercise program along with a planned diet.

Nonalcoholic Steatohepatitis (NASH) Companies and PipelineTherapies:

Elafibranor (GFT505): Genfit
Obeticholic Acid (OCA, Ocaliva): Intercept Pharmaceuticals
Selonsertib (SEL, Formerly GS-4997): Gilead Sciences
Cenicriviroc (CVC): Allergan (Tobira Therapeutics)
Cilofexor (GS-9674): Gilead Sciences
Firsocostat (GS-0976): Gilead Sciences
Aramchol: Galmed Pharmaceuticals Ltd.
Pegbelfermin (BMS-986036): Bristol-Myers Squibb (BMS)
IMM-124E: Immuron
Belapectin (GR-MD-02): Galectin Therapeutics
MSDC-0602K: Cirius Therapeutics
NGM282 (aldafermin): NGM Biopharmaceuticals
JKB-122: TaiwanJ Pharmaceuticals
Semaglutide: Novo Nordisk
MT-3995 (Apararenone): Mitsubishi Tanabe Pharma
LJC242: Novartis Pharmaceuticals
LJN452 (Tropifexor): Novartis Pharmaceuticals
MN-001 (Tipelukast): MediciNova
Resmetirom (MGL-3196): Madrigal Pharmaceuticals
Namodenoson (CF102): Can-Fite BioPharma
ORMD-0801: Oramed Pharmaceuticals
ASC40: Ascletis Pharma
TERN-101: Terns Pharmaceuticals
EYP001: Enyo Pharma

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Nonalcoholic Steatohepatitis (NASH).    

  • In the coming years, the Nonalcoholic Steatohepatitis (NASH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Nonalcoholic Steatohepatitis (NASH) Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Nonalcoholic Steatohepatitis (NASH) treatment market. Several potential therapies for Nonalcoholic Steatohepatitis (NASH) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Nonalcoholic Steatohepatitis (NASH) market size in the coming years.  

  • Our in-depth analysis of the Nonalcoholic Steatohepatitis (NASH) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Nonalcoholic Steatohepatitis (NASH) 

3. Nonalcoholic Steatohepatitis (NASH) Current Treatment Patterns

4. Nonalcoholic Steatohepatitis (NASH) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Nonalcoholic Steatohepatitis (NASH) Late Stage Products (Phase-III)

7. Nonalcoholic Steatohepatitis (NASH) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nonalcoholic Steatohepatitis (NASH) Discontinued Products

13. Nonalcoholic Steatohepatitis (NASH) Product Profiles

14. Nonalcoholic Steatohepatitis (NASH) Key Companies

15. Nonalcoholic Steatohepatitis (NASH) Key Products

16. Dormant and Discontinued Products

17. Nonalcoholic Steatohepatitis (NASH) Unmet Needs

18. Nonalcoholic Steatohepatitis (NASH) Future Perspectives

19. Nonalcoholic Steatohepatitis (NASH) Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: 

Latest Reports By DelveInsight
Nonalcoholic Steatohepatitis (NASH) Market Insight
DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Nonalcoholic Steatohepatitis (NASH) Epidemiology Forecast
DelveInsight’s Nonalcoholic Steatohepatitis (NASH) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Nonalcoholic Steatohepatitis (NASH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Peripherally Inserted Central Catheter (PICC) Devices Market
DelveInsight’s ‘Peripherally Inserted Central Catheter (PICC) Devices Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Peripherally Inserted Central Catheter (PICC) Devices and the historical and forecasted Peripherally Inserted Central Catheter (PICC) Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles